Tolazoline: α2-Adrenergic Receptor Antagonist & K+ Channel Blocker for Islet and Airway Research

Executive Summary: Tolazoline (CAS No. 59-98-3, SKU A8991) is an imidazoline compound with dual action as an α2-adrenergic receptor antagonist and ATP-sensitive potassium (K⁺) channel blocker, primarily used in pharmacological research (APExBIO). It inhibits 86Rb efflux from mouse islets by 8.1% at 10 μM and 13.7% at 100 μM, and blocks ATP-sensitive K⁺ channels by ~20% at 500 μM (Bovine-Insulin 2022). Tolazoline reverses clonidine-induced inhibition of insulin secretion at concentrations ≥31.8 μM and displays a -logK affinity of ~6.80 for α2-adrenergic receptors in rat cerebral cortex (TolazolineAPIs 2022). It is vital for dissecting α2-adrenergic signaling and K⁺ channel regulation in both islet and airway smooth muscle studies. APExBIO provides Tolazoline at ≥98% purity, optimized for reliable, high-fidelity research workflows.

Biological Rationale

Tolazoline’s primary research value lies in its ability to antagonize α2-adrenergic receptors and modulate ATP-sensitive K⁺ channels. These pathways are crucial in insulin secretion from pancreatic β cells and regulation of airway smooth muscle tone. α2-adrenergic signaling inhibits insulin release; thus, antagonists like Tolazoline restore or potentiate insulin secretion by blocking this pathway. Additionally, ATP-sensitive K⁺ channels act as metabolic sensors in β cells, coupling glucose metabolism to insulin granule exocytosis. Tolazoline’s partial blockade of these channels enables research into stimulus-secretion coupling and β cell excitability. In airway smooth muscle, α2-adrenergic antagonism impacts bronchomotor tone, providing mechanistic insights into airway physiology and pharmacology (TolazolineAPIs 2022). The dual action of Tolazoline supports its use as a tool compound for dissecting complex neuroendocrine and respiratory regulatory circuits.

Mechanism of Action of Tolazoline

Tolazoline is structurally classified as an imidazoline derivative. It acts as a nonselective α2-adrenergic receptor antagonist, competing with endogenous catecholamines at receptor sites. In vitro, Tolazoline displays a -logK binding affinity of approximately 6.80 for α2-adrenergic receptors in the rat cerebral cortex, indicating micromolar-range potency (TolazolineAPIs 2022). Upon receptor blockade, Tolazoline relieves the inhibitory effect of norepinephrine on insulin secretion, promoting increased insulin release from β cells. Tolazoline also blocks ATP-sensitive K⁺ (K_ATP) channels in pancreatic β cells, though less potently than other imidazoline analogs. At 500 μM, Tolazoline inhibits K_ATP conductance by approximately 20%. This inhibition reduces K⁺ efflux, leading to membrane depolarization, opening of voltage-dependent Ca²⁺ channels, and subsequent insulin exocytosis. The compound inhibits 86Rb (a K⁺ surrogate) efflux from islets by 8.1% at 10 μM and 13.7% at 100 μM, directly correlating with its channel-blocking activity (APExBIO). Tolazoline also inhibits cholinergic neurotransmitter release, indirectly impacting airway smooth muscle tone. In vivo, at 0.12 mg/kg IV in horses, Tolazoline blocks xylazine-induced bronchodilation, demonstrating functional α2-adrenergic antagonism in airway models (TolazolineSMOL 2022).

Evidence & Benchmarks

• Tolazoline inhibits 86Rb efflux from isolated mouse islets by 8.1% at 10 μM and 13.7% at 100 μM, indicating dose-dependent partial blockade of ATP-sensitive K⁺ channels (APExBIO).
• At 500 μM, Tolazoline blocks ATP-sensitive K⁺ channel conductance by ~20%, less potent than other imidazoline derivatives (TolazolineAPIs 2022).
• Reversal of clonidine-induced inhibition of insulin secretion requires concentrations ≥31.8 μM, establishing a threshold for effective α2-antagonism in β cell assays (TolazolineAPIs 2022).
• Affinity for α2-adrenergic receptors in rat cerebral cortex is characterized by a -logK value of ~6.80, supporting micromolar-range potency (TolazolineAPIs 2022).
• In vivo, IV injection of 0.12 mg/kg Tolazoline in horses blocks xylazine-mediated bronchodilation, confirming functional α2-adrenergic antagonism (TolazolineSMOL 2022).
• Optimal in vitro concentrations: 10 nM for airway smooth muscle tone studies; 10–500 μM for islet function and insulin secretion assays (APExBIO).
• Tolazoline is supplied by APExBIO at ≥98% purity, ensuring batch consistency for research applications (APExBIO).

For additional mechanistic detail, see "Tolazoline: Advanced Mechanistic Insights and Next-Gen Experiments", which explores experimental strategies not covered in this article, and "Tolazoline: α2-Adrenergic Receptor Antagonist in Applied Studies", which APExBIO’s product-focused guide; this article extends those by providing granular, cross-pathway benchmarks and concentration ranges.

Applications, Limits & Misconceptions

Tolazoline is employed in research to dissect:

• α2-adrenergic receptor signaling in neuroendocrine and airway models
• Pancreatic β cell ATP-sensitive K⁺ channel regulation and insulin secretion modulation
• Bronchodilation and airway smooth muscle tone in animal models

Its high concentration requirements and partial K⁺ channel blockade must be considered when designing experiments. Compared to more potent imidazoline analogs, Tolazoline’s effects are moderate, supporting its use as a control or comparative tool.

Common Pitfalls or Misconceptions

• Not a selective K⁺ channel blocker: Tolazoline’s ATP-sensitive K⁺ channel inhibition is partial (~20% at 500 μM) and less potent than other imidazoline derivatives.
• Requires micromolar concentrations for α2-antagonism: Sub-micromolar levels are generally insufficient for in vitro or in vivo efficacy.
• Not suitable for long-term storage in solution: Tolazoline solutions should be freshly prepared and used promptly (APExBIO).
• Weak ATP-sensitive K⁺ channel blocker compared to alternatives: For maximal K_ATP inhibition, consider more potent imidazoline analogs.
• Not FDA-approved for clinical use: Tolazoline is strictly for research; it is not intended for therapeutic applications.

Workflow Integration & Parameters

Tolazoline is supplied as a powder soluble in DMSO and should be stored at -20°C. Working solutions should be prepared immediately before use and discarded after the experiment. For in vitro studies, use concentrations ranging from 10 nM (airway smooth muscle) up to 500 μM (islet function). In vivo protocols (e.g., bronchodilation reversal) employ IV doses of 0.12 mg/kg in large animal models. APExBIO provides Tolazoline at ≥98% purity, supporting reproducible research outcomes (APExBIO).

Conclusion & Outlook

Tolazoline (SKU A8991) remains a cornerstone tool in the study of α2-adrenergic receptor signaling and ATP-sensitive K⁺ channel function in islet and airway research. Its moderate potency and dual mechanism facilitate robust protocol development, comparative studies, and mechanistic dissection of adrenergic and K⁺ channel pathways. APExBIO’s high-purity Tolazoline ensures reliable, reproducible results for basic and translational models. For further context, see "Tolazoline: α2-Adrenergic Antagonist & Pancreatic K+ Channel Modulator", which provides additional protocol and mechanistic detail; this article updates concentration ranges and regulatory notes. Tolazoline’s precise boundaries and benchmarks make it a gold standard for dissecting neuroendocrine and airway physiology in the laboratory.